Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
2023 · Cancer Cell · 158 citations
https://doi.org/10.1016/j.ccell.2023.04.008
W
Wen Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
88
Papers
873
Citations
16
h-index
22
i10-index
Wen Li is an academic researcher from Army Medical University. The author has contributed to research in topics: Breast Cancer Treatment Studies & MRI in cancer diagnosis & Radiomics and Machine Learning in Medical Imaging. The author has an h-index of 16, co-authored 75 publications.
ORCID: 0000-0001-6584-363XPapers by this author
worksTest–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial
2018 · Journal of Magnetic Resonance Imaging · 105 citations
https://doi.org/10.1002/jmri.26539
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
2020 · npj Breast Cancer · 78 citations
https://doi.org/10.1038/s41523-020-00203-7
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
2021 · npj Breast Cancer · 51 citations
https://doi.org/10.1038/s41523-021-00239-3
Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
2016 · PLoS ONE · 19 citations
https://doi.org/10.1371/journal.pone.0142047
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
2024 · Clinical Cancer Research · 12 citations
https://doi.org/10.1158/1078-0432.ccr-23-2928
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat